US4620008A - Processes for the preparation of omeprazole and intermediates therefore - Google Patents
Processes for the preparation of omeprazole and intermediates therefore Download PDFInfo
- Publication number
- US4620008A US4620008A US06/697,396 US69739685A US4620008A US 4620008 A US4620008 A US 4620008A US 69739685 A US69739685 A US 69739685A US 4620008 A US4620008 A US 4620008A
- Authority
- US
- United States
- Prior art keywords
- formula
- hydroxy
- compound
- added
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/68—One oxygen atom attached in position 4
Definitions
- the present invention relates to novel chemical intermediates, a process for their preparation, and their use in the preparation of pharmacologically active substances.
- the present invention provides novel compounds which are useful as intermediates in the preparation of therapeutically active comounds such as benzimidazole derivatives which contain a pyridylmethyl radical of the formula (ii), and methods for the preparation of such compounds.
- Substituted benzimidazoles containing a pyridine radical of the formula (ii) are disclosed i.a. in European patent No. 0005 129.
- a problem with these compounds is their stability characteristics. Upon storage without any special precautions being taken, they are degraded at a rate which is higher than desired. E.g. by storage of omeprazole, which is a substituted benzimidazole disclosed in the patent cited above, at accelerated conditions, that is at +37° C. and at a relative humidity of 80% for a period of 6 months, about 6% of the substance is converted to degradation products.
- the compounds of the formula ##STR4## wherein R is H or CH 3 are novel and useful intermediates in the preparation of pharmaceutically useful compounds, e.g. substituted benzimidazoles of the general formula (i).
- the compounds of the formula I are the products obtained from the preceding nitration reaction (see preparation below), for which the N-oxide form may be considered necessary, and the following substitution reaction in which the pyridine N-oxide form is very advantageous considering the yields.
- N-oxide state of the compounds of the formula I is very advantageous for the subsequent conversion to the 2-hydroxymethylpyridine (procedures A and B).
- Direct hydroxymethylation of the corresponding non-oxidized pyridines ##STR5## only gives low yields ( ⁇ 20%).
- the compounds of the formula I may advantageously be prepared by processing both the nitration step and the substitution step without isolation of the intermediate nitro-pyridine. Furthermore they are stable and can be stored in bulk form.
- the compounds according to the invention of the formula I are useful as intermediates in the preparation of the corresponding 2-hydroxymethylpyridine and reactive derivatives thereof of the formula ##STR6## or a salt thereof, in which formula Z is a hydroxy group or reactive esterified hydroxy group, e.g. halogen such as Cl and p-toluenesulfonyl used for the preparation of e.g. omeprazole.
- omeprazole The reactive intermediate of the formula (iii) is then reacted in known manner with a benzimidazole derivative of the formula ##STR7## whereafter oxidation in known manner of the reaction product of the formula ##STR8## yields omeprazole.
- a preferable method of preparing omeprazole is to use a compound with the general formula I, wherein R is H as an intermediate.
- the most preferable method of preparing omeprazole is to use a compound, wherein R is CH 3 as an intermediate.
- the present invention also relates to a process for the preparation of the compounds of the formula I.
- reaction conditions for the steps (a) and (b) are suitably the following.
- reaction (a) ordinary nitration conditions, i.e., a mixture of conc. sulfuric acid and nitric acid of different concentrations are used. Mixtures containing organic solvents such as acetic acid and nitromethane may also be used.
- a solution of methoxide anion in methanol is preferably used.
- Methoxide salts in inert solvents such as toluene may also be used.
- a solution of methoxide in methanol can be prepared from sodium hydroxide and methanol.
- 2,3,5-trimethyl-pyridine-N-oxide 1457 g, 10 moles was dissolved in conc. H 2 SO 4 (1200 ml, 22.08 moles) in a 50 liters reaction vessel.
- a nitration solution 1750 ml, 32.2 moles conc. H 2 SO 4 and 2065 ml, 29.84 moles 65% HNO 3 ) was added at 90° C. during 1 hour.
- the solution was stirred at 90° for 1.5 hours and thereafter cooled to 30° C.
- the pH of the reaction mixture was then adjusted by adding 10M NaOH (11.65 liters, 116.5 moles) during cooling with water so that the temperature was kept below 40° C.
- the NaOH was added during about 2 hours.
- the reaction sequence is: ##STR14##
- the 2,3,5-trimethylpyridine-N-oxide used as starting material was prepared as follows.
- 3,5-dimethyl-pyridine-N-oxide (3500 g, 28.5 moles) was dissolved in conc. H 2 SO 4 (3500 ml, 64.4 moles). The solution was cooled to 90° C. and nitration solution (5 l, 91.5 moles, conc. H 2 SO 4 and 5.9 l, 85 moles 65% HNO 3 ) was added during 4 hours at 90° C. The solution was stirred at 90° C. over night. The solution was cooled to 30° C. and neutralized with 10M NaOH (36 l, 360 moles) during 4 hours and the temperature kept below 30° C. Acetonitrile (35 liters) was added and the mixture stirred vigorously for 30 minutes. The acetonitrile layer was separated.
- the 3,5-dimethyl-pyridine-N-oxide used as starting material was prepared as follows.
- step 1 To the remainder from step 1 was added NaOH (3300 ml, 10M). The mixture was refluxed for 5 hours, cooled and extracted with CH 2 Cl 2 (8 liters). The phases were separated and the water phase extracted with CH 2 Cl 2 (2 ⁇ 4 liters). The combined CH 2 Cl 2 -phases were dried over MgSO 4 , refluxed with a few grams of decolorizing carbon and filtrated, yielding 3,5-dimethyl-4-methoxy-2-hydroxy-methylpyridine (941 g). The identity of the product was confirmed with 1 H and 13 C NMR.
- Example 2 3.5-Dimethyl-4-methoxypyridine-N-oxide (61.2 g) obtained in Example 2 was dissolved in CH 3 OH (458 ml). Dimethylsulfate (38 ml 0.4 moles) was added dropwise during 15 minutes and pH adjusted to 5.0 using 10M NaOH. The mixture was stirred for 15 minutes and thereafter refluxed for 1 hour. An additional amount of dimethylsulfate (3.8 ml, 0.04 moles) was added dropwise and the mixture was refluxed for 1.5 hours. Stirring was continued overnight at room temperature.
Abstract
Novel compounds of the formula ##STR1## wherein R is H or CH3, a process for their preparation, and their use as intermediates in the preparation of pharmaceutically useful compounds, e.g. substituted benzimidazoles containing a pyridine radical, i.a. omeprazole.
Description
This application is a division of application Ser. No. 526,900, filed on Aug. 26, 1983 now U.S. Pat. No. 4,544,750 issued Oct. 1, 1985.
The present invention relates to novel chemical intermediates, a process for their preparation, and their use in the preparation of pharmacologically active substances.
Compounds of the general formula (i) wherein R1 and R2 are the same or different and are each selected from the group consisting of hydrogen, alkyl, halogen, carbomethoxy, alkoxy and alkanoyl have been disclosed in e.g. European patent No. 0005 129 as useful therapeutical compounds. One of these compounds, known under the generic name omeprazole (R1 =5-OCH3, R2 =H) ##STR2## is being developed as a gastric acid secretion inhibiting drug. It can also be used for providing gastrointestinal cytoprotective effects in mammals and man.
It is important to obtain simple and efficient intermediates and routes of synthesis for omeprazole and, in a more general sense, for therapeutically active compounds such as benzimidazole derivatives containing the pyridylmethyl moiety ##STR3##
The present invention provides novel compounds which are useful as intermediates in the preparation of therapeutically active comounds such as benzimidazole derivatives which contain a pyridylmethyl radical of the formula (ii), and methods for the preparation of such compounds.
Substituted benzimidazoles containing a pyridine radical of the formula (ii) are disclosed i.a. in European patent No. 0005 129. A problem with these compounds is their stability characteristics. Upon storage without any special precautions being taken, they are degraded at a rate which is higher than desired. E.g. by storage of omeprazole, which is a substituted benzimidazole disclosed in the patent cited above, at accelerated conditions, that is at +37° C. and at a relative humidity of 80% for a period of 6 months, about 6% of the substance is converted to degradation products.
It has been found according to the present invention that the compounds of the formula ##STR4## wherein R is H or CH3, are novel and useful intermediates in the preparation of pharmaceutically useful compounds, e.g. substituted benzimidazoles of the general formula (i). The compounds of the formula I are the products obtained from the preceding nitration reaction (see preparation below), for which the N-oxide form may be considered necessary, and the following substitution reaction in which the pyridine N-oxide form is very advantageous considering the yields.
In addition, the N-oxide state of the compounds of the formula I is very advantageous for the subsequent conversion to the 2-hydroxymethylpyridine (procedures A and B). Direct hydroxymethylation of the corresponding non-oxidized pyridines ##STR5## only gives low yields (<20%).
The compounds of the formula I may advantageously be prepared by processing both the nitration step and the substitution step without isolation of the intermediate nitro-pyridine. Furthermore they are stable and can be stored in bulk form. For example, the compounds according to the invention of the formula I are useful as intermediates in the preparation of the corresponding 2-hydroxymethylpyridine and reactive derivatives thereof of the formula ##STR6## or a salt thereof, in which formula Z is a hydroxy group or reactive esterified hydroxy group, e.g. halogen such as Cl and p-toluenesulfonyl used for the preparation of e.g. omeprazole. The reactive intermediate of the formula (iii) is then reacted in known manner with a benzimidazole derivative of the formula ##STR7## whereafter oxidation in known manner of the reaction product of the formula ##STR8## yields omeprazole. A preferable method of preparing omeprazole is to use a compound with the general formula I, wherein R is H as an intermediate. The most preferable method of preparing omeprazole is to use a compound, wherein R is CH3 as an intermediate.
The present invention also relates to a process for the preparation of the compounds of the formula I.
The compounds of the invention of the formula I are prepared according to the invention by
(a) reacting a compound of the formula ##STR9## wherein R is H or CH3, with a nitrating agent such as nitric acid
HNO.sub.3 III
to the formation of a compound of the formula ##STR10## wherein R has the meaning given above whereafter
(b) the compound of the formula IV is directly reacted with methoxide to give the desired end product of the formula ##STR11## wherein R is H or CH3.
The reaction conditions for the steps (a) and (b) are suitably the following.
For reaction (a), ordinary nitration conditions, i.e., a mixture of conc. sulfuric acid and nitric acid of different concentrations are used. Mixtures containing organic solvents such as acetic acid and nitromethane may also be used.
For reaction (b) a solution of methoxide anion in methanol is preferably used. Methoxide salts in inert solvents such as toluene may also be used. A solution of methoxide in methanol can be prepared from sodium hydroxide and methanol.
The utilization of the compounds I in the preparation of reactive derivatives of corresponding 2-hydroxymethylpyridine can be carried out as illustrated below;
A. Procedure useful for the preparation of a compound of the formula (iii) utilizing a compound of the formula I wherein R is CH3 : ##STR12##
B. Procedure useful for the preparation of a compound of the formula (iii) utilizing a compound of the formula I wherein R is H: ##STR13## Suitable sources of free radicals are e.g. (NH4)2 S2 O8 or other salts of persulfuric acid.
The compound of the formula (iii) thus obtained, or a salt thereof, is thereafter in known manner as described in the prior art reacted with the desired benzimidazole derivative (iv) as described above.
The invention is illustrated by the following examples.
2,3,5-trimethyl-pyridine-N-oxide (1457 g, 10 moles) was dissolved in conc. H2 SO4 (1200 ml, 22.08 moles) in a 50 liters reaction vessel. A nitration solution (1750 ml, 32.2 moles conc. H2 SO4 and 2065 ml, 29.84 moles 65% HNO3) was added at 90° C. during 1 hour. The solution was stirred at 90° for 1.5 hours and thereafter cooled to 30° C. The pH of the reaction mixture was then adjusted by adding 10M NaOH (11.65 liters, 116.5 moles) during cooling with water so that the temperature was kept below 40° C. The NaOH was added during about 2 hours. Thereafter CH2 Cl2 (25 liters) was added and the mixture stirred vigorously for 30 minutes. The phases formed were separated and the CH2 Cl2 -phase was transferred to a 100 liters reaction vessel. The water phase was discarded. The methylenechloride was distilled off. To the remainder was added 15 l of toluene which was then distilled off under reduced pressure, followed by another 15 l portion of toluene which was also removed by distillation. 8 liters of methanol was added and the mixture heated to boiling temperature. A solution of NaOH (595 g, 14.9 moles) in CH3 OH (16 liters) was added during about 1.5 hours. The reaction mixture obtained was cooled and its pH adjusted to 8 using conc. H2 SO4 (250 ml, 4.6 moles). Remaining methanol was distilled off and CH2 Cl2 (20 liters) was added to the remainder. The mixture was stirred for about 30 minutes and inorganic salts were filtered off and washed with CH2 Cl2. The filtrates obtained were pooled and evaporated, yielding 1287 g of 2,3,5-trimethyl-4-methoxy-pyridine-N-oxide with a purity of 89%. The identity of the reaction product was confirmed with 1 H and 13 C NMR. 1 H-NMR: δ(COCl3) 2.22(s, 3H), 2.27(s, 3H), 2.51(s, 3H), 3.81(s, 3H), 8.18(s, 1H).
The reaction sequence is: ##STR14## The 2,3,5-trimethylpyridine-N-oxide used as starting material was prepared as follows.
To a 100 liters reaction vessel was added 2,3,5-trimethyl-pyridine (10.9 kg, 89.2 moles) and acetic acid (30 liters). The temperature was raised to 90° C. The mixture was stirred for 3 hours and thereafter cooled to 60° C., whereafter H2 O2 (35% solution, 3122 ml, 35.67 moles) was added during 1 hour. The temperature was then raised to 90° C. The reaction mixture was stirred overnight. After cooling to 40° C. an additional amount of H2 O2 solution (936 ml, 10.7 moles) was added during 1 hour. The temperature was then raised to 90° C. The reaction mixture was stirred for 3 hours and was allowed to stand without heating overnight. Excess of acetic acid was distilled off under vaccum. To the remainder was added NaOH (10M) until pH 10. CH2 Cl2 (10 liters) was added and the resulting mixture was stirred vigorously. The CH2 Cl2 phase was separated and the water phase was extracted twice with CH2 Cl2 (10 liters). The combined CH2 Cl2 -phases were dried over MgSO4 and filtrated. The filtrate was evaporated yielding 2,3,5-trimethyl-pyridine-N-oxide (11920 g, 94% purity). The identity of the product was confirmed with 1 H and 13 C NMR.
3,5-dimethyl-pyridine-N-oxide (3500 g, 28.5 moles) was dissolved in conc. H2 SO4 (3500 ml, 64.4 moles). The solution was cooled to 90° C. and nitration solution (5 l, 91.5 moles, conc. H2 SO4 and 5.9 l, 85 moles 65% HNO3) was added during 4 hours at 90° C. The solution was stirred at 90° C. over night. The solution was cooled to 30° C. and neutralized with 10M NaOH (36 l, 360 moles) during 4 hours and the temperature kept below 30° C. Acetonitrile (35 liters) was added and the mixture stirred vigorously for 30 minutes. The acetonitrile layer was separated. The extraction procedure was repeated with 15 l of acetonitrile, and the combined acetonitrile were extracted with water (10 l at 60° C.). The upper layer was collected and evaporated at reduced pressure (bp 30°-55° C./130 mm Hg). Toluene (10 l) was added and remaining water was thoroughly removed by azeotropic distillation at reduced pressure (bp 55°-65° C./130 mm Hg). Methylalcohol (7 l, 173 moles) was added and the mixture was heated to reflux temperature. A solution of NaOH (1138 g, 28.45 moles) in 30 liters methylalcohol was added over a period of 15 hours. The reaction mixture was cooled and pH adjusted to 9 using conc. HCl (1200 ml, 14 moles). Remaining methanol was evaporated. The residue was cooled and CH2 Cl2 (30 l) and activated carbon (50 g) were added. The mixture was stirred for 30 minutes, filtered and the residue washed with CH2 Cl2. The filtrates were evaporated. The solid product was washed with petroleum ether, (5 liters bp 60°-80° C.) at 50° C. for 30 minutes and filtered. This procedure was repeated once. The product was dried at reduced pressure. Yield 2400 g 3,5-dimethyl-4-methoxypyridine-N-oxide with a purity of 90%. The identity of the product was confirmed with 1 H- and 13 C-NMR. 1 H-NMR: δ(COCl3) 2.23(s, 6H), 3.81(2, 3H), 8.03(s, 2H).
The 3,5-dimethyl-pyridine-N-oxide used as starting material was prepared as follows.
3,5-lutidine (15 kg, 140.2 moles) was dissolved in acetic acid (48 l) at 60° C. Hydrogen peroxide (8430 ml, 98 moles) was added during 3 hours. The solution was heated to 90° C. and kept at this temperature for 3 hours. The reaction mixture was cooled to 60° C. and hydrogen peroxide (3500 ml, 41 moles) was added during 1 hour. The temperature was raised to 90° C. and kept there for 16 hours. The reaction mixture was evaporated at reduced pressure (70° C. 300 mm Hg). The residue (approx 25 liters) was cooled and pH adjusted to 10 with NaOH-solution (23 liters 10M). Acetonitrile (30 liters) was added and the mixture was stirred for 30 minutes. The sodiumacetate was separated off and washed with 10 l acetonitrile. The liquid phase was evaporated at reduced pressure (55° C., 200 mm Hg). The remaining solution (approx 25 liters) was extracted with CH2 Cl2 (20 liters and 3×5 liters). The combined organic layers were dried over MgSO4, filtrated and evaporated at reduced pressure (50° C. 200 mm Hg). When all CH2 Cl2 had distilled off unreacted 3,5-lutidine was evaporated at 75° C., 8 mm Hg. Yield 14940 g of 3,5-dimethylpyridine-N-oxide. The identity was confirmed with .sup. 1 H and 13 C NMR.
The conversion of the compounds of the formula I to 3,5-dimethyl-4-methoxy-2-hydroxymethylpyridine can be carried out according to Procedure A and Procedure B as described above and exemplified below.
2,3,5-dimethyl-4-methoxypyridine-N-oxide (1268 g, 6.75 moles) obtained in Example 1, dissolved in acetic acid (740 ml), was added dropwise to (CH3 CO)2 O (2140 ml) heated to 90° C. The heating was discontinued during the addition. The temperature rose to 130° C. Thereafter the reaction solution was stirred for 1 hour and then cooled to 80° C. whereafter CH3 OH (2460 ml) was added. The reaction solution was evaporated and the remainder used directly in step 2. ##STR16##
To the remainder from step 1 was added NaOH (3300 ml, 10M). The mixture was refluxed for 5 hours, cooled and extracted with CH2 Cl2 (8 liters). The phases were separated and the water phase extracted with CH2 Cl2 (2×4 liters). The combined CH2 Cl2 -phases were dried over MgSO4, refluxed with a few grams of decolorizing carbon and filtrated, yielding 3,5-dimethyl-4-methoxy-2-hydroxy-methylpyridine (941 g). The identity of the product was confirmed with 1 H and 13 C NMR.
3.5-Dimethyl-4-methoxypyridine-N-oxide (61.2 g) obtained in Example 2 was dissolved in CH3 OH (458 ml). Dimethylsulfate (38 ml 0.4 moles) was added dropwise during 15 minutes and pH adjusted to 5.0 using 10M NaOH. The mixture was stirred for 15 minutes and thereafter refluxed for 1 hour. An additional amount of dimethylsulfate (3.8 ml, 0.04 moles) was added dropwise and the mixture was refluxed for 1.5 hours. Stirring was continued overnight at room temperature. Thereafter the mixture was heated to reflux and (NH4)2 S2 O8 (91.2 g, 0.4 moles) dissolved in water (169 ml) was added during 1.75 hours, followed by refluxing for 1.5 hours and stirring at room temperature overnight. Thereafter CH3 OH (452 ml) was added. Precipitated salts were filtered off and discarded. After evaporation of CH3 OH, the remaining water phase (pH 0.6) was adjusted to pH 10.0 using 10M NaOH (145 ml). The water phase was extracted three times with CH2 Cl2. The combined CH2 Cl2 phases were dried over Na2 SO4, evaporated and dried, yielding 3,5-dimethyl-4-methoxy-2-hydroxymethylpyridine (44.2 g). The identity of the product was confirmed with 1 H and 13 C NMR and the purity checked with gas chromatography.
Claims (3)
1. A method for preparing reactive pyridine derivatives of the formula ##STR18## where Z is hydroxy, halogen or p-toluene-sulfonyl, comprising reacting a compound of the formula ##STR19## with dimethyl sulfate to form the intermediate ##STR20## whereafter CH3 OH is added in the presence of a source of free radicals to give a hydroxy compound of the formula ##STR21## and, in the case where Z is not hydroxy, further reacting the hydroxy compound with a reagent selected from the group consisting of halogenating agents or p-toluene sulfonic acid.
2. In a method for the preparation of a compound of the formula ##STR22## by reacting a reactive pyridine derivative of the formula ##STR23## where Z is hydroxy, halogen or p-toluene-sulfonyl, with a substituted benzimidazole, the improvement comprising forming the reactive pyridine derivative by reacting a compound of the formula ##STR24## with dimethyl sulfate to form the intermediate ##STR25## whereafter CH3 OH is added in the presence of a source of free radicals to give a hydroxy compound of the formula ##STR26## and, in the case where Z is not hydroxy, further reacting the hydroxy compound with a reagent selected from the group consisting of halogenating agents and p-toluene sulfonic acid.
3. In a method for the preparation of omeprazole by reacting a reactive pyridine derivative of the formula ##STR27## where Z is hydroxy, halogen, or p-toluene-sulfonyl, with a substituted benzimidazole, the improvement comprising forming the reactive pyridine derivative by reacting a compound of the formula ##STR28## with dimethyl sulfate to form the intermediate ##STR29## whereafter CH3 OH is added in the presence of a source of free radicals to give a hydroxy compound of the formula ##STR30## and, in the case where Z is not hydroxy, further reacting the hydroxy compound with a reagent selected from the group consisting of halogenating agents, and p-toluene sulfonic acid.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE8204879 | 1982-08-26 | ||
SE8204879A SE8204879D0 (en) | 1982-08-26 | 1982-08-26 | NOVEL CHEMICAL INTERMEDIATES |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US06/526,900 Division US4544750A (en) | 1982-08-26 | 1983-08-26 | Certain pyridyl-N-oxide intermediates for the preparation of omeprazole |
Publications (1)
Publication Number | Publication Date |
---|---|
US4620008A true US4620008A (en) | 1986-10-28 |
Family
ID=20347627
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US06/526,900 Expired - Lifetime US4544750A (en) | 1982-08-26 | 1983-08-26 | Certain pyridyl-N-oxide intermediates for the preparation of omeprazole |
US06/697,396 Expired - Lifetime US4620008A (en) | 1982-08-26 | 1985-02-01 | Processes for the preparation of omeprazole and intermediates therefore |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US06/526,900 Expired - Lifetime US4544750A (en) | 1982-08-26 | 1983-08-26 | Certain pyridyl-N-oxide intermediates for the preparation of omeprazole |
Country Status (28)
Country | Link |
---|---|
US (2) | US4544750A (en) |
EP (1) | EP0103553B1 (en) |
JP (1) | JPS5959662A (en) |
KR (1) | KR880000091B1 (en) |
AT (1) | ATE40884T1 (en) |
AU (1) | AU560028B2 (en) |
CA (1) | CA1234118A (en) |
CY (1) | CY1328A (en) |
DD (1) | DD233126A5 (en) |
DE (2) | DE3379222D1 (en) |
DK (1) | DK381583A (en) |
ES (1) | ES8404993A1 (en) |
FI (1) | FI79701C (en) |
GB (1) | GB2126226B (en) |
GR (1) | GR79374B (en) |
HK (1) | HK19486A (en) |
HU (1) | HU189738B (en) |
IE (1) | IE55865B1 (en) |
IL (1) | IL69175A (en) |
IS (1) | IS1438B6 (en) |
MY (1) | MY8600503A (en) |
NO (1) | NO164093C (en) |
NZ (1) | NZ204959A (en) |
OA (1) | OA07498A (en) |
PH (1) | PH17786A (en) |
PT (1) | PT77249B (en) |
SE (1) | SE8204879D0 (en) |
ZA (1) | ZA835143B (en) |
Cited By (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4826531A (en) * | 1986-04-17 | 1989-05-02 | Imperial Chemical Industries Plc | Pyridine derivatives and their uses as fungicides and insecticides |
US4920230A (en) * | 1987-06-29 | 1990-04-24 | Takeda Chemical Industries, Ltd. | Method of producing nitrogen-containing heteroaromatic compounds having an alkoxy group |
DE3840372A1 (en) * | 1988-11-15 | 1990-05-31 | Lentia Gmbh | METHOD FOR THE PRODUCTION OF 3,5-DIMETHYL-4-METHOXYPYRIDINE DERIVATIVES AND A NEW INTERMEDIATE PRODUCT THEREFOR |
US4965269A (en) * | 1989-12-20 | 1990-10-23 | Ab Hassle | Therapeutically active chloro substituted benzimidazoles |
US5221316A (en) * | 1986-04-17 | 1993-06-22 | Imperial Chemical Industries Plc | Fungicides |
US6077541A (en) * | 1997-11-14 | 2000-06-20 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
US6121454A (en) * | 1997-05-06 | 2000-09-19 | Pdi-Research Laboratories, Inc. | Synthesis of pharmaceutically useful pyridine derivatives |
US6174548B1 (en) | 1998-08-28 | 2001-01-16 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
US6245913B1 (en) | 1999-06-30 | 2001-06-12 | Wockhardt Europe Limited | Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole |
US6262086B1 (en) | 1999-08-26 | 2001-07-17 | Robert R. Whittle | Pharmaceutical unit dosage form |
US6262085B1 (en) | 1999-08-26 | 2001-07-17 | Robert R. Whittle | Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
US6268385B1 (en) | 1999-08-26 | 2001-07-31 | Robert R. Whittle | Dry blend pharmaceutical formulations |
US6312712B1 (en) | 1999-08-26 | 2001-11-06 | Robert R. Whittle | Method of improving bioavailability |
US6312723B1 (en) | 1999-08-26 | 2001-11-06 | Robert R. Whittle | Pharmaceutical unit dosage form |
US6316020B1 (en) | 1999-08-26 | 2001-11-13 | Robert R. Whittle | Pharmaceutical formulations |
US6326384B1 (en) | 1999-08-26 | 2001-12-04 | Robert R. Whittle | Dry blend pharmaceutical unit dosage form |
US6353005B1 (en) | 1999-03-02 | 2002-03-05 | Sepracor, Inc. | Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist |
US6362202B1 (en) | 1999-03-02 | 2002-03-26 | Sepracor Inc. | Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists |
US6369087B1 (en) | 1999-08-26 | 2002-04-09 | Robert R. Whittle | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
US6437139B1 (en) | 1997-05-06 | 2002-08-20 | Pdi-Research Laboratories, Inc. | Synthesis of pharmaceutically useful pyridine derivatives |
US6489346B1 (en) | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
US6555139B2 (en) | 1999-06-28 | 2003-04-29 | Wockhardt Europe Limited | Preparation of micron-size pharmaceutical particles by microfluidization |
US6645988B2 (en) | 1996-01-04 | 2003-11-11 | Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
US20040006111A1 (en) * | 2002-01-25 | 2004-01-08 | Kenneth Widder | Transmucosal delivery of proton pump inhibitors |
US6699885B2 (en) | 1996-01-04 | 2004-03-02 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and methods of using same |
US6733778B1 (en) | 1999-08-27 | 2004-05-11 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
US6780880B1 (en) | 1999-08-26 | 2004-08-24 | Robert R. Whittle | FT-Raman spectroscopic measurement |
US20080312449A1 (en) * | 1993-05-28 | 2008-12-18 | Per Lennart Lindberg | New Compounds |
CN101648907B (en) * | 2009-09-14 | 2011-08-03 | 南京第一农药集团有限公司 | Purifying method of 2-chloromethyl-4-methoxyl-3,5-dimethylpyridine chloride |
CN102603620A (en) * | 2012-01-13 | 2012-07-25 | 江苏中邦制药有限公司 | Synthetic method of chloromethylpyridine or pyridine derivative hydrochloride of chloromethylpyridine |
US8815916B2 (en) | 2004-05-25 | 2014-08-26 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
USRE45198E1 (en) | 1996-01-04 | 2014-10-14 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
US8906940B2 (en) | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
US8993599B2 (en) | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
CN114805193A (en) * | 2022-04-19 | 2022-07-29 | 南京红太阳医药研究院有限公司 | Preparation method of omeprazole intermediate |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE8404065D0 (en) * | 1984-08-10 | 1984-08-10 | Haessle Ab | NOVEL BIOLOGICALLY ACTIVE COMPOUNDS |
SE8504409D0 (en) * | 1985-09-24 | 1985-09-24 | Haessle Ab | NOVEL CHEMICAL INTERMEDIATES |
ES2026761A6 (en) * | 1990-10-31 | 1992-05-01 | Genesis Para La Investigacion | A process for the preparation of omeprazol. |
ES2036948B1 (en) * | 1991-11-21 | 1994-09-01 | Genesis Para La Investigacion | PROCEDURE FOR OBTAINING COMPOUNDS DERIVED FROM PIRIDINE. |
ES2060541B1 (en) * | 1993-02-26 | 1995-11-16 | Vinas Lab | NEW PROCEDURE FOR THE SYNTHESIS OF A DERIVATIVE OF 2- (2-PIRIDILMETILSUFINIL) BENCIMIDAZOLE, AND NEW INTERMEDIATE PRODUCTS OBTAINED WITH THE SAME. |
ES2097089B1 (en) * | 1995-02-01 | 1997-12-16 | Esteve Quimica Sa | PROCEDURE FOR THE PREPARATION OF 2-HYDROXIMETIL-3,5-DIMETIL-4-METOXIPIRIDINA. |
WO1999033807A2 (en) * | 1997-12-24 | 1999-07-08 | Pdi-Research Laboratories, Inc. | Synthesis of pharmaceutically useful pyridine derivatives (intermediates) employing free radical substitution reactions to functionalize the 2-position of the pyridine |
GB9717849D0 (en) * | 1997-08-23 | 1997-10-29 | Seal Sands Chemicals Limited | Preparation of pyridene derivatives |
KR100396431B1 (en) | 1998-01-26 | 2003-09-02 | 가부시키가이샤 구라레 | Method for producing 2-sulfonylpyridine derivatives and method for producing 2-[((2-pyridyl)methyl)thio]-1h-benzimidazole derivatives |
US6350876B2 (en) | 1998-01-26 | 2002-02-26 | Kuraray Co., Ltd. | 4-chloro-3,5-dimethyl-2-sulfonyl pyridines |
US6303787B1 (en) | 1998-05-27 | 2001-10-16 | Natco Pharma Limited | Intermediates and an improved process for the preparation of Omeprazole employing the said intermediates |
WO2000000474A1 (en) * | 1998-06-26 | 2000-01-06 | Russinsky Limited | Pyridine building blocks as intermediates in the synthesis of pharmaceutically active compounds |
GB9921578D0 (en) * | 1999-09-13 | 1999-11-17 | Cipla Limited | Omeprazole synthesis |
ES2171116B1 (en) * | 2000-04-14 | 2003-08-01 | Esteve Quimica Sa | PROCEDURE FOR OBTAINING DERIVATIVES OF (((PIRIDIL REPLACED) METAL) UNCLE) BENCIMIDAZOL. |
AU2000258410A1 (en) * | 2000-07-28 | 2003-12-02 | Herbex, Produtos Quimicos, Sa | New method for the preparation of the anti-ulcer compounds omeprazole, lansoprazole and pantoprazole |
OA13134A (en) | 2001-05-11 | 2006-12-13 | Tibotec Pharm Ltd | Broadspectrum 2-amino-benzoxazole sulfamide HIV protease inhibitors. |
FR2848555B1 (en) | 2002-12-16 | 2006-07-28 | Negma Gild | ENANTIOMER (-) OF TENATOPRAZOLE AND ITS THERAPEUTIC APPLICATION |
CN100376574C (en) * | 2006-06-14 | 2008-03-26 | 浙江大学 | Preparation process of taytrolazole |
EP2114919A2 (en) | 2007-01-31 | 2009-11-11 | Krka Tovarna Zdravil, D.D., Novo Mesto | Process for the preparation of optically pure omeprazole via salt formation with a chiral amine or treatment with an entiomer converting enzyme and chromatographic seperation |
CN101648912B (en) * | 2009-09-14 | 2012-07-04 | 南京第一农药集团有限公司 | Continuous preparation method of 4-nitro-3,5-dimethylpyridine-N-oxide |
AU2020354581A1 (en) | 2019-09-24 | 2022-03-03 | Prolacta Bioscience, Inc. | Compositions and methods for treatment of inflammatory and immune diseases |
CN112142653B (en) * | 2020-10-22 | 2022-02-11 | 成都百泉生物医药科技有限公司 | Preparation method of omeprazole intermediate |
CN113307773A (en) * | 2021-06-17 | 2021-08-27 | 上海毕得医药科技股份有限公司 | 6-bromo-3-methoxy-1-phenyl-1H-indazole and synthetic method and application thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2663711A (en) * | 1951-12-08 | 1953-12-22 | Du Pont | Process for the preparation of pyridine alcohols from pyridine n-oxides |
US2735851A (en) * | 1956-02-21 | Alkanolpykroine-n-oxides | ||
US4215126A (en) * | 1975-07-31 | 1980-07-29 | Smith Kline & French Laboratories Limited | Alkoxy pyridine compounds |
US4255431A (en) * | 1978-04-14 | 1981-03-10 | Aktiebolaget Hassle | Gastric acid secretion inhibiting substituted 2-(2-benzimidazolyl)-pyridines, pharmaceutical preparations containing same, and method for inhibiting gastric acid secretion |
EP0080602A1 (en) * | 1981-11-05 | 1983-06-08 | Byk Gulden Lomberg Chemische Fabrik GmbH | Substituted benzimidazoles, process for their preparation, their use and medicaments containing them |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58135881A (en) * | 1981-11-05 | 1983-08-12 | ビク−グルデン・ロムベルク・ヘミツシエ・フアブリク・ゲゼルシヤフト・ミト・ベシユレンクテル・ハフツング | Substituted benzimidazoles, manufacture and use and medicine |
-
1982
- 1982-08-26 SE SE8204879A patent/SE8204879D0/en unknown
-
1983
- 1983-06-30 DE DE8383850185T patent/DE3379222D1/en not_active Expired
- 1983-06-30 AT AT83850185T patent/ATE40884T1/en not_active IP Right Cessation
- 1983-06-30 DE DE198383850185T patent/DE103553T1/en active Pending
- 1983-06-30 EP EP83850185A patent/EP0103553B1/en not_active Expired
- 1983-07-06 IL IL69175A patent/IL69175A/en not_active IP Right Cessation
- 1983-07-06 CA CA000431863A patent/CA1234118A/en not_active Expired
- 1983-07-14 ZA ZA835143A patent/ZA835143B/en unknown
- 1983-07-20 OA OA58065A patent/OA07498A/en unknown
- 1983-07-20 NZ NZ204959A patent/NZ204959A/en unknown
- 1983-07-20 AU AU17101/83A patent/AU560028B2/en not_active Expired
- 1983-07-28 IE IE1787/83A patent/IE55865B1/en not_active IP Right Cessation
- 1983-08-02 NO NO832794A patent/NO164093C/en not_active IP Right Cessation
- 1983-08-08 PH PH29368A patent/PH17786A/en unknown
- 1983-08-18 DD DD83254056A patent/DD233126A5/en unknown
- 1983-08-19 DK DK381583A patent/DK381583A/en not_active Application Discontinuation
- 1983-08-24 ES ES525122A patent/ES8404993A1/en not_active Expired
- 1983-08-25 PT PT77249A patent/PT77249B/en unknown
- 1983-08-25 HU HU832987A patent/HU189738B/en unknown
- 1983-08-25 CY CY1328A patent/CY1328A/en unknown
- 1983-08-25 JP JP58154250A patent/JPS5959662A/en active Granted
- 1983-08-25 GB GB08322866A patent/GB2126226B/en not_active Expired
- 1983-08-25 FI FI833047A patent/FI79701C/en not_active IP Right Cessation
- 1983-08-26 GR GR72304A patent/GR79374B/el unknown
- 1983-08-26 IS IS2845A patent/IS1438B6/en unknown
- 1983-08-26 US US06/526,900 patent/US4544750A/en not_active Expired - Lifetime
- 1983-08-26 KR KR1019830004003A patent/KR880000091B1/en not_active IP Right Cessation
-
1985
- 1985-02-01 US US06/697,396 patent/US4620008A/en not_active Expired - Lifetime
-
1986
- 1986-03-20 HK HK194/86A patent/HK19486A/en not_active IP Right Cessation
- 1986-12-30 MY MY503/86A patent/MY8600503A/en unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2735851A (en) * | 1956-02-21 | Alkanolpykroine-n-oxides | ||
US2663711A (en) * | 1951-12-08 | 1953-12-22 | Du Pont | Process for the preparation of pyridine alcohols from pyridine n-oxides |
US4215126A (en) * | 1975-07-31 | 1980-07-29 | Smith Kline & French Laboratories Limited | Alkoxy pyridine compounds |
US4255431A (en) * | 1978-04-14 | 1981-03-10 | Aktiebolaget Hassle | Gastric acid secretion inhibiting substituted 2-(2-benzimidazolyl)-pyridines, pharmaceutical preparations containing same, and method for inhibiting gastric acid secretion |
US4337257A (en) * | 1978-04-14 | 1982-06-29 | Aktiebolaget Hassle | Gastric acid secretion inhibiting substituted 2-(2-benzimidazolyl)-pyridines, their preparation, pharmaceutical preparations containing same, and method for inhibiting gastric acid secretion |
EP0080602A1 (en) * | 1981-11-05 | 1983-06-08 | Byk Gulden Lomberg Chemische Fabrik GmbH | Substituted benzimidazoles, process for their preparation, their use and medicaments containing them |
Non-Patent Citations (4)
Title |
---|
Bullitt et al., Journal of the American Chemical Society, vol. 76, No. 5, pp. 1370 1371, Mar. 5, 1954. * |
Bullitt et al., Journal of the American Chemical Society, vol. 76, No. 5, pp. 1370-1371, Mar. 5, 1954. |
March, Advanced Organic Chemistry, Reactions, Mechanisms and Structure, Second Edition, pp. 392 394. * |
March, Advanced Organic Chemistry, Reactions, Mechanisms and Structure, Second Edition, pp. 392-394. |
Cited By (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4826531A (en) * | 1986-04-17 | 1989-05-02 | Imperial Chemical Industries Plc | Pyridine derivatives and their uses as fungicides and insecticides |
US5112386A (en) * | 1986-04-17 | 1992-05-12 | Imperial Chemical Industries Plc | Fungicides |
US5221316A (en) * | 1986-04-17 | 1993-06-22 | Imperial Chemical Industries Plc | Fungicides |
US4920230A (en) * | 1987-06-29 | 1990-04-24 | Takeda Chemical Industries, Ltd. | Method of producing nitrogen-containing heteroaromatic compounds having an alkoxy group |
DE3840372A1 (en) * | 1988-11-15 | 1990-05-31 | Lentia Gmbh | METHOD FOR THE PRODUCTION OF 3,5-DIMETHYL-4-METHOXYPYRIDINE DERIVATIVES AND A NEW INTERMEDIATE PRODUCT THEREFOR |
US5066810A (en) * | 1988-11-15 | 1991-11-19 | Cl Pharma Aktiengesellschaft | 3,5-dimethyl-4-methoxypyridine derivatives |
US4965269A (en) * | 1989-12-20 | 1990-10-23 | Ab Hassle | Therapeutically active chloro substituted benzimidazoles |
US20100222591A1 (en) * | 1993-05-28 | 2010-09-02 | Per Lennart Lindberg | New Compounds |
US20080312449A1 (en) * | 1993-05-28 | 2008-12-18 | Per Lennart Lindberg | New Compounds |
US20050004171A1 (en) * | 1996-01-04 | 2005-01-06 | Phillips Jeffrey O. | Novel substituted benzimidazole dosage forms and method of using same |
US6780882B2 (en) | 1996-01-04 | 2004-08-24 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
USRE45198E1 (en) | 1996-01-04 | 2014-10-14 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
US6699885B2 (en) | 1996-01-04 | 2004-03-02 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and methods of using same |
US20030215527A1 (en) * | 1996-01-04 | 2003-11-20 | Phillips Jeffrey Owen | Novel substituted benzimidazole dosage forms and method of using same |
US6645988B2 (en) | 1996-01-04 | 2003-11-11 | Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
US6489346B1 (en) | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
US6437139B1 (en) | 1997-05-06 | 2002-08-20 | Pdi-Research Laboratories, Inc. | Synthesis of pharmaceutically useful pyridine derivatives |
US6121454A (en) * | 1997-05-06 | 2000-09-19 | Pdi-Research Laboratories, Inc. | Synthesis of pharmaceutically useful pyridine derivatives |
US6780435B2 (en) | 1997-11-14 | 2004-08-24 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
US20030113376A1 (en) * | 1997-11-14 | 2003-06-19 | Chih-Ming Chen | Omeprazole formulation |
US6077541A (en) * | 1997-11-14 | 2000-06-20 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
US6096340A (en) * | 1997-11-14 | 2000-08-01 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
US6174548B1 (en) | 1998-08-28 | 2001-01-16 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
US6855336B2 (en) | 1998-08-28 | 2005-02-15 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
US20040131684A1 (en) * | 1998-08-28 | 2004-07-08 | Chih-Ming Chen | Omeprazole formulation |
US6552045B2 (en) | 1999-03-02 | 2003-04-22 | Sepracor Inc. | Methods and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists |
US6362202B1 (en) | 1999-03-02 | 2002-03-26 | Sepracor Inc. | Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists |
US6548518B2 (en) | 1999-03-02 | 2003-04-15 | Sepracor, Inc. | Methods of treating gastro-esophogeal reflux disease using (-) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists |
US6353005B1 (en) | 1999-03-02 | 2002-03-05 | Sepracor, Inc. | Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist |
US6555139B2 (en) | 1999-06-28 | 2003-04-29 | Wockhardt Europe Limited | Preparation of micron-size pharmaceutical particles by microfluidization |
US6245913B1 (en) | 1999-06-30 | 2001-06-12 | Wockhardt Europe Limited | Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole |
US6312723B1 (en) | 1999-08-26 | 2001-11-06 | Robert R. Whittle | Pharmaceutical unit dosage form |
US6312712B1 (en) | 1999-08-26 | 2001-11-06 | Robert R. Whittle | Method of improving bioavailability |
US6667321B2 (en) | 1999-08-26 | 2003-12-23 | Robert R. Whittle | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
US6667323B1 (en) | 1999-08-26 | 2003-12-23 | Robert R. Whittle | Dry-blend pharmaceutical formulations |
US6316020B1 (en) | 1999-08-26 | 2001-11-13 | Robert R. Whittle | Pharmaceutical formulations |
US6268385B1 (en) | 1999-08-26 | 2001-07-31 | Robert R. Whittle | Dry blend pharmaceutical formulations |
US6706737B2 (en) | 1999-08-26 | 2004-03-16 | Robert R. Whittle | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
US20040157887A1 (en) * | 1999-08-26 | 2004-08-12 | Whittle Robert R. | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
US6444689B1 (en) | 1999-08-26 | 2002-09-03 | Robert R. Whittle | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
US6653329B1 (en) | 1999-08-26 | 2003-11-25 | Robert R. Whittle | Granulated pharmaceutical formulations and methods for making the same |
US6262085B1 (en) | 1999-08-26 | 2001-07-17 | Robert R. Whittle | Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
US6780880B1 (en) | 1999-08-26 | 2004-08-24 | Robert R. Whittle | FT-Raman spectroscopic measurement |
US6262086B1 (en) | 1999-08-26 | 2001-07-17 | Robert R. Whittle | Pharmaceutical unit dosage form |
US6667324B1 (en) | 1999-08-26 | 2003-12-23 | Robert R. Whittle | Dry blend pharmaceutical formulations |
US6326384B1 (en) | 1999-08-26 | 2001-12-04 | Robert R. Whittle | Dry blend pharmaceutical unit dosage form |
US6369087B1 (en) | 1999-08-26 | 2002-04-09 | Robert R. Whittle | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
US6733778B1 (en) | 1999-08-27 | 2004-05-11 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
US20040006111A1 (en) * | 2002-01-25 | 2004-01-08 | Kenneth Widder | Transmucosal delivery of proton pump inhibitors |
US8993599B2 (en) | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
US8815916B2 (en) | 2004-05-25 | 2014-08-26 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
US8906940B2 (en) | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
CN101648907B (en) * | 2009-09-14 | 2011-08-03 | 南京第一农药集团有限公司 | Purifying method of 2-chloromethyl-4-methoxyl-3,5-dimethylpyridine chloride |
CN102603620A (en) * | 2012-01-13 | 2012-07-25 | 江苏中邦制药有限公司 | Synthetic method of chloromethylpyridine or pyridine derivative hydrochloride of chloromethylpyridine |
CN102603620B (en) * | 2012-01-13 | 2014-10-29 | 江苏中邦制药有限公司 | Synthetic method of chloromethylpyridine or pyridine derivative hydrochloride of chloromethylpyridine |
CN114805193A (en) * | 2022-04-19 | 2022-07-29 | 南京红太阳医药研究院有限公司 | Preparation method of omeprazole intermediate |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4620008A (en) | Processes for the preparation of omeprazole and intermediates therefore | |
KR950011748B1 (en) | Sulfenamide derivatives and their production | |
US3201406A (en) | Pyridylcoumarins | |
US3793314A (en) | Cinnamic acid esters of 7-nitro-8-hydroxy-quinoline | |
US4886912A (en) | Cyanoguanidine derivative and process for preparation thereof | |
US3803202A (en) | Process for the production of 2-cyano-3,4,5,6-tetrahalogenbenzoic acid alkyl esters | |
KR950014792B1 (en) | Benzimidazole derivatives and process for their preparations | |
KR910006983B1 (en) | Process for the preparation of pyridine derivatives | |
US4160096A (en) | Process for production of 5-nitroimidazole derivatives | |
HU193454B (en) | Process for producing 3-phenyl-butyraldehyde derivatives | |
KR940006531B1 (en) | Process for preparation of pyridine derivatives | |
US4681943A (en) | 1-acyl-1-(2-pyridinyl)semicarbazides | |
US3751462A (en) | Process for preparation of substituted fluoromethanesulfonanilides | |
KR910009956B1 (en) | Process for preparation of benzimidazol derivatives | |
US4028369A (en) | Preparation of glycol (2-(p-chlorophenoxy)-2-methylpropionate)-2-nicotinate | |
KR790001309B1 (en) | Process for prepaing uracil derivatives | |
JPH0780812B2 (en) | Azulene derivative thromboxane synthetase inhibitor and process for producing the same | |
JPH06228103A (en) | New octahydroacridine derivative and its production | |
KR920007270B1 (en) | Method of preparing for pyridine | |
KR810000481B1 (en) | Process for the preparation of substituted n-(carboxymethyl) 1-3-aminopropane-2-ol | |
IL44119A (en) | Esters of 1,6-dimethyl-10alpha-metho esters of 1,6-dimethyl-10alpha-methoxy-8beta-hydroxyethylergo -ine and process for their preparation | |
US4946959A (en) | Method of preparing 5-alkyl-1-(2-pyridinyl)-1H-1,2,4-triazol-3-ols | |
Morisawa et al. | Modification at the 2-Position of 4-Deoxypyridoxol and α4-Norpyridoxol | |
JPS6134428B2 (en) | ||
JPS6113474B2 (en) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
FPAY | Fee payment |
Year of fee payment: 12 |